Real-World Utilization Pattern and Outcomes of Letermovir in Adult Cytomegalovirus-Seropositive Allogeneic Hematopoietic Cell Transplant Recipients: An International Retrospective Study From the Infectious Diseases Working Party of EBMT. | Synapse
March 4, 20260 citations
Real-World Utilization Pattern and Outcomes of Letermovir in Adult Cytomegalovirus-Seropositive Allogeneic Hematopoietic Cell Transplant Recipients: An International Retrospective Study From the Infectious Diseases Working Party of EBMT.
To assess the real-world utilization and outcomes of letermovir in preventing CMV in allogeneic hematopoietic cell transplant recipients.
Conducted an international retrospective study
Analyzed CMV infection rates post-allo-HCT
Evaluated letermovir usage patterns among recipients
Observed low incidence of cytomegalovirus infections compared to previous reports
Demonstrated effectiveness of letermovir in real-world settings
Provided insights into management of CMV prophylaxis in transplant recipients
Abstract
An analysis of real-world use of letermovir in CMV prophylaxis after allo-HCT showed a low incidence of csCMVi compared to previously published information.